UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia
Clinical trial NCT02222688 · COMPLETED
Trial details
- NCT number
- NCT02222688
- Sponsor
- Thomas Kipps
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-08-08
- Primary completion
- 2017-10-10
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.